Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
7
×
life sciences
national blog main
new york blog main
7
×
new york top stories
amgen
boston top stories
clinical trials
national top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
novartis
alirocumab
alnylam pharmaceuticals
eli lilly
evolocumab
fda
fremanezumab
inclisiran
regeneron pharmaceuticals
teva pharmaceutical
alder biopharmaceuticals
What
drug
7
×
new
7
×
approval
cholesterol
fda
medicines
bio
brings
class
companies
drugs
lowering
medco
migraine
roundup
wave
won
acquire
advantages
agreed
alnylam
amgen
arguments
bar
based
big
billion
biogen’s
biopharmaceutical
candidates
cash
commercialized
company
competitors
compound
convo
data
deal
decades
developed
Language
unset
Current search:
new
×
drug
×
" boston blog main "
×
biotech
×
" new york blog main "
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
MedCo Touts New Data for Long-Lasting Heart Drug as Reckoning Looms
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines